EP1283674A4 - Therapie von proliferativen störungen durch direkte bestrahlung von zellenkernen mit tritierten mitteln zur kern-spezifischen verabreichung - Google Patents

Therapie von proliferativen störungen durch direkte bestrahlung von zellenkernen mit tritierten mitteln zur kern-spezifischen verabreichung

Info

Publication number
EP1283674A4
EP1283674A4 EP01928305A EP01928305A EP1283674A4 EP 1283674 A4 EP1283674 A4 EP 1283674A4 EP 01928305 A EP01928305 A EP 01928305A EP 01928305 A EP01928305 A EP 01928305A EP 1283674 A4 EP1283674 A4 EP 1283674A4
Authority
EP
European Patent Office
Prior art keywords
therapy
proliferative disorders
cell nuclei
targeting agents
direct irradiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01928305A
Other languages
English (en)
French (fr)
Other versions
EP1283674A2 (de
Inventor
Robert A Gatenby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of EP1283674A2 publication Critical patent/EP1283674A2/de
Publication of EP1283674A4 publication Critical patent/EP1283674A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP01928305A 2000-03-24 2001-03-16 Therapie von proliferativen störungen durch direkte bestrahlung von zellenkernen mit tritierten mitteln zur kern-spezifischen verabreichung Withdrawn EP1283674A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19215300P 2000-03-24 2000-03-24
US192153P 2000-03-24
US19267100P 2000-03-28 2000-03-28
US192671P 2000-03-28
PCT/US2001/008446 WO2001072203A2 (en) 2000-03-24 2001-03-16 Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targeting agents

Publications (2)

Publication Number Publication Date
EP1283674A2 EP1283674A2 (de) 2003-02-19
EP1283674A4 true EP1283674A4 (de) 2005-04-27

Family

ID=26887786

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01928305A Withdrawn EP1283674A4 (de) 2000-03-24 2001-03-16 Therapie von proliferativen störungen durch direkte bestrahlung von zellenkernen mit tritierten mitteln zur kern-spezifischen verabreichung

Country Status (3)

Country Link
EP (1) EP1283674A4 (de)
AU (1) AU2001255179A1 (de)
WO (1) WO2001072203A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490434A1 (de) * 1990-12-10 1992-06-17 Akzo Nobel N.V. Markierte, modifizierte Oligonokleotiden
WO1994015646A1 (en) * 1993-01-07 1994-07-21 Thomas Jefferson University Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation
US5847104A (en) * 1995-05-22 1998-12-08 Hybridon, Inc. Method of tritium labeling oligonucleotide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0490434A1 (de) * 1990-12-10 1992-06-17 Akzo Nobel N.V. Markierte, modifizierte Oligonokleotiden
WO1994015646A1 (en) * 1993-01-07 1994-07-21 Thomas Jefferson University Antisense inhibition of c-myc to modulate the proliferation of smooth muscle cells
US5847104A (en) * 1995-05-22 1998-12-08 Hybridon, Inc. Method of tritium labeling oligonucleotide
US5821354A (en) * 1996-11-26 1998-10-13 Angiogene Inc. Radiolabeled DNA oligonucleotide and method of preparation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STRAUME T ET AL: "Transmitted proliferation disadvantage from mouse oocytes labeled in vivo with [3H]thymidine: radiosensitive target considerations.", MUTATION RESEARCH. 4 MAR 1997, vol. 374, no. 1, 4 March 1997 (1997-03-04), pages 11 - 19, XP008043131, ISSN: 0027-5107 *
TAN W ET AL: "An efficient synthesis of radioisotopically labeled oligonucleotides through direct solid-phase 5'-phosphitylation", TETRAHEDRON LETTERS 1995 UNITED KINGDOM, vol. 36, no. 30, 1995, pages 5323 - 5326, XP002318770, ISSN: 0040-4039 *
WILEY L M ET AL: "Radiosensitive target in the early mouse embryo exposed to very low doses of ionizing radiation.", MUTATION RESEARCH. 1 AUG 1994, vol. 309, no. 1, 1 August 1994 (1994-08-01), pages 83 - 92, XP008043130, ISSN: 0027-5107 *

Also Published As

Publication number Publication date
WO2001072203A3 (en) 2002-10-10
EP1283674A2 (de) 2003-02-19
WO2001072203A2 (en) 2001-10-04
AU2001255179A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
US5484778C1 (en) Phthalocynine photosensitizers for photodynamic therapy and methods for their use
AP2002002663A0 (en) Tropane derivatives useful in therapy
ATE524218T1 (de) Apparat zur verabreichung einer asymmetrischen strahlungsdosis
PT1212327E (pt) Pirazolopirimidinas como agentes terapeuticos
GB2361399B (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
CY2008007I1 (el) Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου
EP1690323A4 (de) Verfahren zum modulieren von laserbeschleunigten protonen für die strahlungstherapie
IL173395A0 (en) Pyridazine derivatives and their use as therapeutic agents
NO20040239L (no) Konjugater av makrosykliske metallkomplekser med biomolekyler og anvendelse derav til fremstilling av midler for anvendelse i NMR- og røntgendiagnose, samt ved strålebehandling
AU2003302892A8 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
GB2370745B (en) High definition conformal arc radiation therapy with muti-leaf collimator
AP2004003147A0 (en) Tropane derivatives useful in therapy
EP1404366A4 (de) Kombinationstherapie mit gamma-interferon und b-zellspezifischen antikörpern
GB2393123B (en) Halogenated tetraphenylporphyrins and their uses as radiosensitizers for radiation therapy
GB0000832D0 (en) Energy absorbing pocket member
AU4557001A (en) Induction of beta cell differentiation in human cells by stimulation of the glp-1 receptor
AU1264200A (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
EP1283674A4 (de) Therapie von proliferativen störungen durch direkte bestrahlung von zellenkernen mit tritierten mitteln zur kern-spezifischen verabreichung
GB0120318D0 (en) System and method for optimizing radiation treatment with an intensity modulating multi-leaf collimator
AU2001286398A1 (en) Apparatus for determining the position of radioactive seeds in needles used for radioactive seed therapy for prostate cancer
ID26831A (id) Pengalih suplai daya
AU2204400A (en) Monte carlo simulation of neutron transport for use in radiotherapy
AU2001288448A1 (en) Agents for neutron capture therapy
IL156447A0 (en) Dapd combination therapy with inosine monophosphate dehydrogenase inhibitors
EP1214403A4 (de) VERFAHREN ZUR ERZEUGUNG VON IMMUNKOMPATIBLEN ZELLEN UND GEWEBEN UNTER VERWENDUNG VON NUKLEäREN TRANSFERTECHNIKEN

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021014

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 51/04 B

Ipc: 7A 01N 43/04 A

A4 Supplementary search report drawn up and despatched

Effective date: 20050311

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061003